Navigation Links
Intensive blood sugar treatment in trial of diabetes and cardiovascular disease changed
Date:2/6/2008

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has stopped one treatment within a large, ongoing North American clinical trial of diabetes and cardiovascular disease 18 months early due to safety concerns after review of available data, although the study will continue.

In this trial of adults with type 2 diabetes at especially high risk for heart attack and stroke, the medical strategy to intensively lower blood glucose (sugar) below current recommendations increased the risk of death compared with a less-intensive standard treatment strategy. Study participants receiving intensive blood glucose lowering treatment will now receive the less-intensive standard treatment.

The ACCORD (Action to Control Cardiovascular Risk in Diabetes) study enrolled 10,251 participants. Of these, 257 in the intensive treatment group have died, compared with 203 within the standard treatment group. This is a difference of 54 deaths, or 3 per 1,000 participants each year, over an average of almost four years of treatment. The death rates in both groups were lower than seen in similar populations in other studies.

A thorough review of the data shows that the medical treatment strategy of intensively reducing blood sugar below current clinical guidelines causes harm in these especially high-risk patients with type 2 diabetes, said Elizabeth G. Nabel, M.D., director, NHLBI. Though we have stopped this part of the trial, we will continue to care for these participants, who now will receive the less-intensive standard treatment. In addition, we will continue to monitor the health of all participants, seek the underlying causes for this finding, and carry on with other important research within ACCORD.

In stopping this part of the trial, Nabel accepted the recommendation of the 10-member Data and Safety Monitoring Board (DSMB) an independent advisory group of experts in diabetes, cardiovascular disease, ep
'/>"/>

Contact: NHLBI Communications Office
NHLBI_news@nhlbi.nih.gov
301-496-4236
NIH/National Heart, Lung and Blood Institute
Source:Eurekalert

Page: 1 2 3 4 5

Related medicine news :

1. Susan G. Komen for the Cure Sharing Grassroots Advocacy Knowledge With International Representatives in Intensive Dallas Training Session
2. Intensive training post-spinal cord injury can stimulate repair in brain and spinal cord
3. Intensive care quality of sleep improved by new drug, reports study
4. Smoking Cessation Rates Double With Intensive Counseling and Free Nicotine Replacement Therapy, Studies of 20,000 Smokers Show
5. Browns Wives Host Special Day at MetroHealth Medical Center to Support the Neonatal Intensive Care Unit
6. Large intensive care study reveals vital recommendations for treatment of brain injury patients
7. Dangerous Condition Underscores Importance of Home Blood Pressure Monitoring
8. Cord Blood America Supports Trend From New York, California for States to Inform Parents of the Advantages of Umbilical Cord Blood Storage
9. Novel small molecule therapy shows benefit for anemic patients via hydration of red blood cells
10. Research shows a daily does of beetroot juice can beat high blood pressure
11. Hospital Patients Blood Clot Risk High
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... The Plantrician Project , a ... tools and resources for healthcare professionals and their ... world’s leading online cooking school, have joined forces ... Culinary Rx. As an online food and nutrition ... for debut spring 2015, will be designed to ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Eufaula, Oklahoma, ... to Lake Eufaula, the state’s largest lake with more ... town is home to a little more than 3,000 ... P.M. on Saturday, the 6th of December. , Featuring ... way through downtown Eufaula on Main Street. Narconon ...
(Date:12/19/2014)... Abilene, TX (PRWEB) December 20, 2014 ... XC, a new injectable filler from respected cosmetic brand ... can occur naturally with age. The Medspa at Hendrick ... new development in skin care technology to its clients. ... filler gel to be FDA-approved to treat the mid-face ...
(Date:12/19/2014)... The intestinal bacteria that cause inflammatory bowel disease, which ... researchers report. The findings, published recently in the ... to prevent the disease and treat the 1.6 million ... "The intestinal bacteria, or ,gut microbiome, you develop ... impact on your health for the rest of your ...
(Date:12/19/2014)... -- Injectable drug users who also use cocaine and ... other substance users, a new study finds. "We ... of suicide attempt and completed suicide," Didier Jutras-Aswad, a ... a university news release. "However, there are many different ... among substance users were actually more likely to attempt ...
Breaking Medicine News(10 mins):Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 3Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 4Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2Health News:Crohn's, Colitis May Have Genetic Underpinnings, Study Finds 2Health News:Cocaine, Amphetamines May Up Injection Drug Users' Suicide Risk 2
... In keeping with its,commitment to wellness, and following ... Michigan, a leading HMO in the state, is building ... employees at the,workplace., BCN, which is the HMO ... year instituted Wellness Works!, an employee health,and fitness program ...
... Larry Kocot and Robert,Seidman Headline Agenda at FDA/CMS ... medicine has,progressed beyond a topic of industry insider ... public and private payers. Value isn,t a new,concept ... mean for buying and,selling biopharmaceuticals? How is value ...
... FDA Approval, Agreement will Broaden Access to ... Cholesterol-Reducing Medicine, ... USA (GSK) and Merck & Co., Inc.,Whitehouse Station, NJ, USA ... over-the-counter (OTC) marketing rights for,MEVACOR(R) (lovastatin). Under the agreement, GSK ...
... N.J., Nov. 26 Pharmasset, Inc.,(Nasdaq: VRUS ... President,Marketing & Sales, responsible for coordinating the global ... Mr. Higgins, who,has served as a consultant to ... Marketing, Virology at Hoffmann-LaRoche, Inc. His areas,of expertise ...
... also hinder progress, study finds , MONDAY, Nov. 26 ... ("good") cholesterol increase the risk of memory problems and ... , The study also found that high levels of ... meat, also boosts post-stroke disability. , "People with low ...
... prevent osteoporosis, researchers say , , MONDAY, Nov. 26 (HealthDay News) ... than do non-depressed women in the same age range, a ... pronounced in certain regions of the hip, which is troubling ... -- and potentially fatal -- consequences of osteoporosis. , ...
Cached Medicine News:Health News:Leading by Example: Blue Care Network of Michigan Shows How Employers Can Improve Employee Wellness 2Health News:Defining the Value of Medicine in an Evidence-Based Healthcare Marketplace 2Health News:Defining the Value of Medicine in an Evidence-Based Healthcare Marketplace 3Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 2Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 3Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 4Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 5Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 6Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 7Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 8Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 9Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 10Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 11Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 12Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 13Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 14Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 15Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 16Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 17Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 18Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 19Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 20Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 21Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 22Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 23Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 24Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 25Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 26Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 27Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 28Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 29Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 30Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 31Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 32Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 33
(Date:12/19/2014)... -- In the Friday, December 19 edition of USA ... Technology (HIT) features Konica Minolta, the company announced today. The supplement ... leading healthcare organizations. In addition to the print ... as New York , Chicago ... Minneapolis and San Francisco ...
(Date:12/19/2014)... 19, 2014 TODAY, AEGATE, the ... World announced the appointment of Peter Fox ... Chief Channels and Partner Officer. Peter has ... to its acquisition by Oracle in 2011. ... Geneva and subsequently Convergys, a world ...
(Date:12/19/2014)... , Dec. 19, 2014  Newport Corporation (NASDAQ: ... Kadia, Ph.D. has joined the company,s Board of ... Officer and a director of Evans Analytical Group, ... evaluation and analytical services to companies in a ... to joining Evans Analytical Group, Dr. Kadia spent ...
Breaking Medicine Technology:USA Today Supplement Featuring Konica Minolta Focuses on Impact of Healthcare IT 2Aegate Appoints new CTO and Chief Channels & Partner Officer 2Aegate Appoints new CTO and Chief Channels & Partner Officer 3Aegate Appoints new CTO and Chief Channels & Partner Officer 4Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2
... Amarin Corporation plc (Nasdaq: AMRN ) ... on cardiovascular disease, today announced that, in connection with ... Shares ("ADSs"), the underwriters of the offering have exercised ... aggregate of 1,800,000 additional ADSs to cover over-allotments.  The ...
... 7, 2011 Echo Therapeutics, Inc. (OTC Bulletin Board: ... Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous ... transdermal drug delivery, today announced that Patrick T. Mooney, ... Echo Therapeutics will present at the OneMedForum 2011 annual ...
Cached Medicine Technology:Amarin Announces Underwriters' Exercise of Over-Allotment Option 2Amarin Announces Underwriters' Exercise of Over-Allotment Option 3Amarin Announces Underwriters' Exercise of Over-Allotment Option 4Echo Therapeutics to Present at the OneMedForum 2011 Conference 2
0.3 mm diameter hemi-ball tip....
ICL manipulator with textured micro-ball tip....
Vaulted shank. For engaging the inferior haptic without touching the dome of the IOL....
... ophthalmoscopes are individually adjusted for perfect focus ... not on paper. This, along with Keeler's ... ensures that whatever the patient's pupil size, ... field of view. Lithium-ion technology provides a ...
Medicine Products: